News

The Charcot-Marie-Tooth Association (CMTA) Board of Directors announced Sept. 28 that it has approved a $225,483 award to Dr. Mario Saporta at the University of Miami for a study on the use of antisense oligonucleotides (ASOs) to treat CMT2E. CMT is ...

This CMT awareness month, the CMTA’s Chief Research Officer, Katherine Forsey, PhD, shares her perspective as a CMT mum and how she navigated her own child’s participation in CMT research. Charcot-Marie-Tooth disease (CMT) affects the peripheral nerves; the nerves that ...

New York, NY – September 12, 2023 — The Muscular Dystrophy Association (MDA) and Charcot-Marie-Tooth Association (CMTA) today announced a collaborative research grant totaling $299,992 to test gene delivery to Schwann cells using nanoparticles to treat CMT1X. The three-year study, ...

The Charcot-Marie-Tooth Association July 17 hailed the news that global healthcare giant Novartis is acquiring DTx Pharma and its CMT1A therapy DTx-1252 as a significant step forward for the acceleration of novel CMT treatments capable of reaching the peripheral nervous ...

Professor Robert Burgess and his team at The Jackson Laboratory in Bar Harbor, Maine, is developing both drug treatments and gene therapies for CMT2D with excellent results in mouse models of the disease. CMT2D is caused by mutations in a gene ...